Cogent Biosciences Email Formats
Biotechnology Research • 
Waltham, Massachusetts, United States • 201-500 Employees
Cogent Biosciences Email Formats
Cogent Biosciences uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@cogentbio.com), used 63.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@cogentbio.com | 63.9% |
{first name}.{last name} | john.doe@cogentbio.com | 34.8% |
Key Contacts at Cogent Biosciences
Jay Chatfield
Medical Affairs Strategy/Medical Affairs Director - Oncology, Hematology, Immunology Rare Disease
Sahar Reka
Director, Global Regulatory Affairs Oncology
John Owens
Executive Director
Amy Wall
Sr Director Pv Operations
Nisha Shah
Senior Director, Pharmacovigilance Scientist
Sarina Hoda
Senior Director, Total Rewards
Bhaswati Sengupta
Associate Director Of Translational Medicine
Dena Westphalen
Director, Scientific Affairs
Lisa Sundquist
Area Director East, Field Medical Affairs
Sasha Zbitnoff
Senior Director, Late Stage Development
Company overview
| Headquarters | 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US |
| Phone number | +16179455576 |
| Website | |
| NAICS | 541714 |
| Keywords | Oncology, Kinase Inhibitors, Systemic Mastocytosis, Gastrointestinal Stromal Tumors (Gist) |
| Founded | 2014 |
| Employees | 201-500 |
| Socials |
About Cogent Biosciences
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Cogent Biosciences has 108 employees across 11 departments.
Departments
Number of employees
Funding Data
Explore Cogent Biosciences's funding history, including investment rounds, total capital raised, and key backers.
Cogent Biosciences Tech Stack
Discover the technologies and tools that power Cogent Biosciences's digital infrastructure, from frameworks to analytics platforms.
WordPress themes
JavaScript libraries
JavaScript libraries
Page builders
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
JavaScript libraries
JavaScript frameworks
Singapore
United Kingdom
Belgium
Frequently asked questions
4.8
40,000 users
